회복된 B형간염 환자에서 Rituximab 치료 이후 발생한 전격성 간부전을 동반한 B형간염 바이러스의 재활성화 1예Fulminant Hepatic Failure with Hepatitis B Virus Reactivation after Rituximab Treatment in a Patient with Resolved Hepatitis B
- Other Titles
- Fulminant Hepatic Failure with Hepatitis B Virus Reactivation after Rituximab Treatment in a Patient with Resolved Hepatitis B
- Authors
- 정승민; 손주현; 김태엽; 유기덕; 안용우; 배중호; 전용철; 최정혜
- Issue Date
- Apr-2010
- Publisher
- 대한소화기학회
- Keywords
- Hepatitis B; Reactivation; HBsAg; Rituximab; Lymphoma
- Citation
- 대한소화기학회지, v.55, no.4, pp.266 - 269
- Indexed
- SCOPUS
KCI
- Journal Title
- 대한소화기학회지
- Volume
- 55
- Number
- 4
- Start Page
- 266
- End Page
- 269
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/175082
- DOI
- 10.4166/kjg.2010.55.4.266
- ISSN
- 1598-9992
- Abstract
- It is well known that the reactivation of hepatitis B virus (HBV) may occur as an acute hepatitis after chemotherapy or immunosuppressive therapy. Although most of these cases have been reported in HBsAg-positive patients, there have been a few reports of HBV reactivation in HBsAg-negative patients. There have been concerns for the need to screen the reactivation as well as anti-viral prophylaxis in HBsAg-negative patients with possible HBV occult infection who are planning to undergo chemotherapy or immunosuppressive therapy. Rituximab, an anti-CD20 monoclonal antibody, is effective in the treatment of non-Hodgkin’s lymphoma. However, rituximab can affect the immunity against HBV, consequently increasing viral replication. In fact, there have been reports of HBV reactivation after treatment with rituximab. Here, we report a case of HBV reactivation following rituximab plus systemic chemotherapy in diffuse large B cell lymphoma patient who was HBsAg negative, anti-HBs positive, and anti-HBc positive, ultimately leading to treatment-unresponsive fulminant hepatic failure.
- Files in This Item
-
Go to Link
- Appears in
Collections - 서울 의과대학 > 서울 내과학교실 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/175082)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.